ME Therapeutics Holdings, Inc. (TSE:METX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
ME Therapeutics Holdings Inc., a company specializing in immuno-oncology cancer therapies, has granted 250,000 stock options to a consultant, exercisable at $3.51 per share over the next three years. These options will vest in increments, with a hold period of four months and one day from the date of issuance. The company continues its focus on novel cancer treatments targeting immune suppression.
For further insights into TSE:METX stock, check out TipRanks’ Stock Analysis page.